|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
R Pieters, LF Thompson, GJ Broekema, DR Huismans, GJ Peters, ST Pals, E Horst, K Hahlen and AJ Veerman
Department of Pediatrics, Free University Hospital, Amsterdam, The
Netherlands.
Ecto-5'nucleotidase (5'NT; CD73) expression was studied with a monoclonal
antibody (7G2) and a radiochemical assay and compared with the expression
of other antigens in B-cell-lineage leukemias on cells from 100 leukemic
patients and two cell lines. A B-cell origin was confirmed by the
expression of CD19 and HLA-DR. Four stages of B-cell leukemias were
defined: stage I (pro-B) as CD10-, cytoplasmic mu- (c mu- ), surface Ig-
(sIg-); stage II (cALL) as CD10+/c mu-/sIg-; stage III (pre-B) as CD10+ or
-/c mu+/sIg-; and stage IV (B) as CD10-/c mu-/sIg+. A linear correlation
was found between immunohistochemical and radiochemical determination of
5'NT (r = .86). 5'NT expression was low in T-cell leukemias and stage I,
high in stages II and III, and low again in stage IV of B-cell leukemias.
5'NT expression was not related to c mu, CD20, CD21, CD22, CD34, and
terminal deoxynucleotidyl transferase (TdT) expression, but was
significantly related to CD10 and inversely related to kappa/lambda
expression. However, the 5'NT activity in CD10+ leukemias (stages II and
III) shows a very wide range. Within the group of CD10+ leukemias no
differences were detected between 5'NT+ and 5'NT- cells in their expression
of other B-cell antigens. We conclude that the place of 5'NT in leukemias
corresponding to early stages of B-cell development has been characterized.
5'NT is expressed in CD10+ stages and decreases before the expression of
sIgs. Future studies should make clear whether a high expression of this
enzyme in CD10+ stages is a normal maturation phenomenon or a malignant
phenomenon.
This article has been cited by other articles:
| |||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 1991 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
